Viread

pitfalls potholes trouble challenge jump avoid struggle problem

Biotech

Antios hep B drug slows viral rebound, but FDA hold casts shadow

Antios Therapeutics’ hepatitis B therapy slowed the virus’s rebound in a midstage trial, but an FDA hold casts a shadow over results.

Annalee Armstrong Jun 27, 2022 11:41am

Wall Street

Barclays loses patience with Gilead, tells it to change up its strategy

Mar 10, 2017 4:16am